Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01213017 · ClinicalTrials.gov registry record · Phase 3
The Effect of Certolizumab Pegol on MRI Synovitis and Bone Edema in Rheumatoid Arthritis Patients
A Phase 3 study, sponsored by Oklahoma Medical Research Foundation.
- Completed
- Registry status
- Phase 3
- Development phase
- 20
- Enrollment target
NCT01213017 is a Phase 3 study that has completed, run by Oklahoma Medical Research Foundation. The registered enrollment target is 20 participants.
The verdict
NCT01213017, a Phase 3 study, has completed, sponsored by Oklahoma Medical Research Foundation.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 20 participants
- Enrollment target
Study Summary
The purpose of this study is to determine whether Certolizumab pegol can rapidly reduce the inflammatory changes and inhibit erosions on hand and wrist MRI in patients with active moderate to severe rheumatoid arthritis.
Interventions
- DRUG certolizumab pegol
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2010-09 |
| Est. Completion | 2012-04 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01213017
The ClinicalTrials.gov registry entry for NCT01213017 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Oklahoma Medical Research Foundation, which has 12 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which certolizumab pegol is the first listed.
NCT01213017 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01213017 about?
NCT01213017 is a clinical study titled "The Effect of Certolizumab Pegol on MRI Synovitis and Bone Edema in Rheumatoid Arthritis Patients". The purpose of this study is to determine whether Certolizumab pegol can rapidly reduce the inflammatory changes and inhibit erosions on hand and wrist MRI in patients with active moderate to severe rheumatoid arthritis.
What is the current status of trial NCT01213017?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 20 participants. The study started on 2010-09. Estimated completion is 2012-04.
What interventions are being tested in trial NCT01213017?
The interventions under investigation include: certolizumab pegol (DRUG).
Who is sponsoring clinical trial NCT01213017?
This trial is sponsored by Oklahoma Medical Research Foundation, which has 12 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.